| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
1 company
Nuechterlein Carole serves as a Director, 10% Owner at ALGS. Across recent SEC filings that breaks down to 1 buy and 0 sells. Those positions are worth an estimated $8.3M at current prices.
The biggest single holding is ALGS (~$8.3M) as Director, 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 7,933,601 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 25, 2023 | ALGS Aligos Therapeutics, Inc. | Director, 10% Owner | Buy | 7,933,601 | $0.76 | $6,004,149.24 | +256.6% | +10.8% | -41.2% |